COMMUNIQUÉS West-GlobeNewswire

Once Esteemed Institutions Are Corrupted, States President of the Association of American Physicians and Surgeons (AAPS)
25/03/2024
TUCSON, Ariz., March 25, 2024 (GLOBE NEWSWIRE) -- The institutions and experts we have long relied on are now contaminated with intellectual, moral, and ethical rot, writes ophthalmologist Jane Lindell Hughes , M.D., F. [...]
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25/03/2024
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is [...]
Type 1 diabetes researchers from across Canada sign letter of support for diabetes research to be included in the upcoming federal budget
25/03/2024
TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Top researchers in the field of type 1 diabetes (T1D) signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal [...]
Des chercheurs sur le diabète de type 1 de partout au Canada signent une lettre de soutien pour que la recherche sur le diabète soit incluse dans le prochain budget fédéral
25/03/2024
TORONTO, 25 mars 2024 (GLOBE NEWSWIRE) -- Des chercheurs de premier plan dans le domaine du diabète de type 1 (DT1) ont signé une lettre ouverte en faveur du renouvellement du financement du Partenariat FRDJ-IRSC pour [...]
Transactions in Connection with Share Buy-back Program
25/03/2024
Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Revive Drip’s Expert IV Nurses Bring Alternative Wellness Solutions to the Greater Puget Sound Area
25/03/2024
Revive Drip delivers fast and effective IV hydration in the comfort of your home. GIG HARBOR, WA, March 25, 2024 (GLOBE NEWSWIRE) -- Revive Drip, a leading mobile intravenous therapy (IV) company providing customized [...]
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
25/03/2024
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport [...]
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
25/03/2024
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, [...]
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
25/03/2024
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) [...]
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
25/03/2024
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial investigating PLX038 (PEG~SN- [...]
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
25/03/2024
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced [...]
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
25/03/2024
HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines Altamira Therapeutics [...]
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
25/03/2024
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company [...]
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
25/03/2024
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic [...]
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
25/03/2024
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company [...]
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
25/03/2024
- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV [...]
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
25/03/2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the [...]
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
25/03/2024
Key Highlights: Cholesterol Efflux Mediator TM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program nearing [...]
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
25/03/2024
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73 rd Annual Scientific Session (ACC.24 [...]

Pages